# Sanofi’s AccelRare tool helps whittle it down to the top five diagnosis of the child, in a matter of 10 minutes.

*biotech · news · 2026-05-26 · The Hindu Business Line*

## Key points

- Sanofi India's AccelRare AI tool provides rare disease pre-diagnosis in just 10 minutes.
- AccelRare covers 310 rare diseases with an 88 percent diagnosis accuracy for healthcare practitioners.
- The tool was co-developed by 67 rare disease experts and validated across 13 disease networks.
- AccelRare requires no registration, collects no patient identification, and is free for users.
- AccelRare is approved as a Class A medical device in India and Class I in Europe.

**Companies:** Sanofi
**Countries:** India

[Read the full story on The Hindu Business Line](https://www.thehindubusinessline.com/news/national/sanofi-indias-digital-tool-helps-identify-300-plus-rare-diseases/article71026000.ece)

---

Canonical: https://newsio.io/n/2d77fb3c-8840-45c1-afe2-58d64de1a292/sanofis-accelrare-tool-helps-whittle-it-down-to-the-top-five-diagnosis-of-the-ch
Summarized by Newsio from The Hindu Business Line. https://newsio.io/how-it-works